INFU

Business Context and Reporting Period

Company: HAPC, Inc. (filing as Infusystem Holdings, Inc. in metadata, but registrant is HAPC, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Status: Development stage "blank check" company formed in August 2005 to acquire healthcare businesses.
Key Event: On September 29, 2006, the company entered into a definitive Stock Purchase Agreement to acquire InfuSystem, Inc., a provider of ambulatory infusion pump systems. The transaction is subject to stockholder approval and is expected to close by April 30, 2007.

Key Financial Metrics

Debt & Liquidity: The company has no long-term debt as of December 31, 2006. However, upon closing the InfuSystem acquisition, it will incur a secured promissory note payable to I-Flow Corporation ranging from $55,000,000 to $75,000,000. Liquidity outside the trust account is limited to approximately $427,000, which is intended to fund transaction costs and working capital until closing.

Material Changes vs. Prior Period

• Capital Structure: Completed an Initial Public Offering (IPO) in April 2006, raising net proceeds of approximately $98 million. This resulted in a massive increase in total assets and equity compared to the prior period.
• Trust Account: Established a trust account holding approximately $98.15 million, invested in U.S. Treasury money market funds, to fund the business combination or liquidation.
• Operating Results: The net loss increased significantly to $7.86 million. This was driven primarily by non-cash expenses, including $19.7 million in compensation expense (stock-based) and a $10.8 million non-cash gain on warrant liabilities which partially offset the losses.
• Strategic Shift: Transitioned from a search phase to a definitive acquisition phase with the signing of the agreement to purchase InfuSystem for $140 million.

Guidance, Outlook, Risks, and Contingencies

Outlook & Guidance: Management anticipates completing the acquisition of InfuSystem by April 30, 2007. If the acquisition is not consummated by April 18, 2008 (24 months post-IPO), the company will liquidate and distribute trust proceeds to public stockholders.

Material Risks:

• Acquisition Failure: If stockholders reject the deal or the deal fails, the company may lack time/resources to find an alternative target and will be forced to liquidate.
• Leverage: Post-acquisition, the company will be highly leveraged with debt between $55M and $75M, limiting operational flexibility.
• Regulatory & Operational Risks (InfuSystem): InfuSystem faces risks related to Medicare reimbursement rates, shortages of chemotherapy drugs (e.g., 5-Fluorouracil), and a pending use tax liability to the State of Michigan (approx. $1.5 million).
• Internal Controls: Management identified a material weakness in financial reporting controls regarding the accounting of warrant liabilities, though remedial actions are underway.

Unusual Items: The financial statements include significant non-cash items, specifically the valuation of warrant liabilities (classified as liabilities under EITF 00-19) and substantial stock-based compensation expenses.

Investor Verification Checklist

• Stockholder Approval: Verify the outcome of the stockholder vote required to approve the InfuSystem acquisition (deadline April 30, 2007).
• Redemption Rights: Confirm the percentage of shares redeemed by dissenting stockholders, as this directly impacts the cash portion of the purchase price and the size of the promissory note owed to I-Flow.
• Michigan Tax Liability: Monitor the status of InfuSystem's appeal regarding the $1.5 million use tax liability to the State of Michigan.
• Financing Terms: Review the final terms of the promissory note to I-Flow, including interest rates and covenants, once the transaction closes.
• Internal Control Remediation: Assess the progress of remedial actions taken to address the material weakness in financial reporting controls.